ChemDiv, a chemistry-driven contract research organisation (CRO) based in San Diego, US and with strong ties to Russia, has consolidated its presence in Eastern Europe and Eurasia by acquiring Prudentas, a CRO that runs Phase I-IV clinical trials in Russia and Ukraine.

No financial terms were disclosed for the acquisition, which was made through ChemRar High Tech Center, ChemDiv’s Moscow-based business incubator for drug discovery, development and commercialisation. Prudentas will continue to operate independently under its own name as ‘Prudentas LLC, a ChemDiv Group company’.

With headquarters in Moscow, Prudentas has specialised in the early stages of drug development since its formation in March 2007. Combining with ChemDiv will give Prudentas’ clients a “unique opportunity” to evaluate compounds from preclinical testing through to proof-of-concept studies, said the latter’s chief executive officer (CEO), Dmitry Prudnikov.

ChemDiv has already worked with Prudentas in the past, and the acquisition reinforces the activities of ChemDiv’s Discovery outSource offering while providing synergies with the CRO’s Chemical Diversity Research Institute and other discovery services operations such as Drugs Technology, Ltd, which offers good laboratory practice/good manufacturing practice-standard formulation as well as chemistry, manufacturing and controls services.

The investment capitalises on the growing trend for offshoring clinical trials to Eastern Europe, encouraged by the availability of naive patient populations, rapid and efficient trial recruitment and high-data quality across a broad range of therapeutic categories including central nervous system, cardiovascular and metabolic disorders, oncology, inflammation, and infectious diseases – areas already served by the Discovery outSource operation, noted Nikolay Savchuk, president and CEO of ChemDiv.

“This acquisition further strengthens and expands our global presence specifically in the Eastern European and Eurasian markets, and responds to growing customer demand for comprehensive R&D outsourcing,” he commented.